2ⁿᵈ Edition of the Cancer R&D World Conference 2026

Scientific Sessions

Artificial Intelligence and Machine Learning in Precision Oncology

Artificial intelligence (AI) and machine learning (ML) are revolutionizing precision oncology by transforming how cancer is detected, diagnosed, and treated. These technologies analyze vast amounts of genomic, clinical, and imaging data to uncover hidden patterns that guide personalized treatment strategies. AI-driven tools are enhancing tumor classification, predicting drug responses, and optimizing clinical decision-making with unprecedented accuracy. Machine learning algorithms also accelerates drug discovery and biomarker identification, helping researchers design therapies tailored to each patient’s unique cancer profile.

At the Cancer Research and Development Conference 2026, this session will spotlight how AI and ML are advancing precision oncology from research to clinical application. Experts will discuss innovations in predictive modeling, data integration, and ethical considerations surrounding algorithmic medicine. Join us as we explore how intelligent technologies are reshaping the future of cancer care, making it more predictive, personalized, and precise than ever before.

Related Sessions

Current Landscape and Future Directions of Oncology Research
Oncogenic Signaling Pathways and Therapeutic Targets
Emerging Biomarkers for Cancer Detection and Prognosis
Cancer Prevention and Early Detection Strategies
Immuno-Oncology and Cell-Based Therapies
Innovations in Immuno-Oncology
Cytokine Modulation and Immune Adjuvants in Cancer Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy: Clinical Progress and Challenges
Next-Generation Cell and Gene Therapies in Oncology
Liquid Biopsy and Circulating Tumor DNA (ctDNA) Diagnostics
Companion Diagnostics
Artificial Intelligence and Machine Learning in Precision Oncology
Next-Generation Targeted Therapies: KRAS, HER2, BRAF, and NRAS
Overcoming Drug Resistance: Mechanisms and Solutions
Oncology Pipeline
Trends in Antibody–Drug Conjugates (ADCs)
Launch of Novel mAb Products for Cancer Therapy